We are live on ! Find out more
HA

Harfst & Associates Portfolio holdings

AUM $643M
1-Year Est. Return 24.12%
This Fund
S&P 500
This Quarter Est. Return
+7.98%
1 Year Est. Return
+24.12%
3 Year Est. Return
+82.48%
5 Year Est. Return
+108.64%
10 Year Est. Return
+384.36%
AUM
$190M
AUM Growth
-$58.1M
Cap. Flow
-$71.2M
Cap. Flow %
-37.52%
Top 10 Hldgs %
83.31%
Holding
104
New
3
Increased
18
Reduced
42
Closed
30

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$2.3M
2
SYK icon
Stryker
SYK
+$2.21M
3
RTN
Raytheon Company
RTN
+$2.19M
4
GD icon
General Dynamics
GD
+$2.17M
5
MDT icon
Medtronic
MDT
+$2.16M

Sector Composition

Rank Sector Weight
1 Financials 39.97%
2 Consumer Staples 5.39%
3 Technology 1.75%
4 Healthcare 1.45%
5 Consumer Discretionary 1.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TXN icon
101
Texas Instruments
TXN
$254B
-33,543
Closed -$2.1M
RDS.B
102
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
-18,810
Closed -$1.31M
BHI
103
DELISTED
Baker Hughes
BHI
-25,570
Closed -$1.16M
DO
104
DELISTED
Diamond Offshore Drilling
DO
-24,830
Closed -$600K

Similar funds

Harfst & Associates's Q3 2016 Portfolio in Review

As of Q3 2016, Harfst & Associates held 104 positions worth $190M, down 23% from $248M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Harfst & Associates withdrew a net $71.2M in Q3 2016, closing 30 positions and reducing 42 holdings. Its most notable exit was Eli Lilly, an estimated $2.3M position sold in full.

By sector, the portfolio is most concentrated in Financials at 40% of assets, up from 29% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Harfst & Associates opened a new position in iShares Core US Aggregate Bond ETF worth $365K.

  • Harfst & Associates's largest Q3 2016 buy was iShares Core US Aggregate Bond ETF: 3,249 shares worth $365K.
  • Harfst & Associates added most to iShares Core S&P 500 ETF in Q3 2016, an estimated $1.84M increase.
  • Harfst & Associates's biggest Q3 2016 reduction was Stryker, cutting an estimated $2.21M.
  • Harfst & Associates fully exited Eli Lilly in Q3 2016, selling an estimated $2.3M.
  • Harfst & Associates's ten largest holdings make up 83% of its $190M portfolio in Q3 2016.
  • Harfst & Associates opened 3 new positions and closed 30 in Q3 2016.
  • Harfst & Associates's portfolio value fell 23% quarter-over-quarter to $190M.

Based on Harfst & Associates's 13F filing for Q3 2016, filed 14 Nov 2016.